MedPath

Efficacy of Cryotherapy Combined With Intralesional Tuberculin PPD Versus Intralesional Tuberculin PPD in Treatment of Multiple Common Warts

Phase 3
Conditions
Common Wart
Interventions
Biological: Tuberculin purified protein derivative
Registration Number
NCT04288817
Lead Sponsor
Assiut University
Brief Summary

The investigate the efficacy and safety of combined 'cryo-immuno-therapy' versus intralesional tuberculin purified protein derivative (PPD) antigen immunotherapy alone for multiple common warts

Detailed Description

Common warts are benign skin lesions caused by the human papillomavirus (HPV). The dorsal surface of the hands and fingers are the main predilection sites. Cryotherapy is frequently used to eradicate common warts via necrotic destruction of HPV-infected keratinocytes or by inducing of an effective cell-mediated immune response. However, the cure rates of cryotherapy are only around (44-47%) .

Intralesional antigen immunotherapy represents a promising therapeutic approach for the treatment of different types of warts, particularly if multiple and/or recalcitrant.

The investigate the efficacy and safety of combined 'cryo-immuno-therapy' versus intralesional tuberculin purified protein n immunotherapy alone for multiple common warts.

Although intralesional immunotherapy - compared to conventional therapeutic methods - has been generally along with better outcome, lower incidence of side effects and less recurrence, it is not still approved as a standard method of treatment in patients with wart , because the majority of available studies are open-labeled and randomized, placebo-controlled trials are very scarce.

The immune system plays an important role in the spontaneous resolution of warts. The immune mechanisms against HPV include the development of cell-mediated immune response with activation of T helper1 (Th1) lymphocytes resulting in long-term immunity . Stimulation of the immune system would clear warts in other locations, eliminating the need for the local treatment for each individual wart .

Multiple studies support the use of intralesional PPD injection as an effective and valuable treatment option due to its systemic effect, especially for patients with multiple warts, with the benefit of clearance of both treated and distant warts.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
40
Inclusion Criteria
  1. A dults older than 18 years
  2. multiple (>3 warts) common warts .
  3. not currently using other treatments for a wart .
  4. not had relapsed at least once after treatment with any of the tissue-destructive modalities.
  5. Positive tuberculin skin test.
Exclusion Criteria
  • Acute febrile illness, history of asthma, allergic skin disorders.-1 2- Pregnancy or lactation. 3- Cold-induced diseases. 4- Immunosuppression.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Cryotherapy and intralesional tuberculin PPDTuberculin purified protein derivativeEfficacy of cryotherapy combined with intralesional tuberculin purified protein in treatment of multiple common warts
Intralesional tuberculin PPDTuberculin purified protein derivativeEfficacy of Intralesional tuberculin purified protein deravative monotherapy in the treatment of multiple common warts
Primary Outcome Measures
NameTimeMethod
Number of lesions4 months

The following grading system will be used to evaluate treatment response:

\*Complete response: responders who show 100% improvement (disappearance of all warts and return to normal skin markings).

Marked response: responders who show 76 to 99% decrease in number and/or decrease in apparent size, as assessed by a clinician and photographic evaluation also known as near-complete response.

* Moderate response: partial responders show 25 to 75% improvement.

* No or minimal response: less than 25% decrease in size/numbers of all warts. the study

Size of lesionsTwo months

By decreasing in size after treatment and compare the response of the lesions tow treatment lines

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath